Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INVA NASDAQ:KNSA OTCMKTS:NWBO NASDAQ:PHAT NASDAQ:PLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINVAInnoviva$22.95-0.2%$23.01$16.52▼$25.15$1.70B0.38712,445 shs244,956 shsKNSAKiniksa Pharmaceuticals International$56.28-2.3%$46.40$24.85▼$58.20$4.31B0.17706,780 shs267,271 shsNWBONorthwest Biotherapeutics$0.21-2.4%$0.21$0.19▼$0.37$343.21M-0.742.90 million shs1.83 million shsPHATPhathom Pharmaceuticals$12.29-4.5%$11.52$2.21▼$18.31$979.80M0.571.22 million shs584,428 shsPLRXPliant Therapeutics$1.21+1.3%$1.29$1.09▼$1.95$74.61M1.2696,746 shs162,229 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINVAInnoviva0.00%-1.07%+0.52%+10.05%+23.45%KNSAKiniksa Pharmaceuticals International0.00%+26.74%+13.21%+22.93%+99.89%NWBONorthwest Biotherapeutics0.00%+2.31%-1.63%-30.07%-34.01%PHATPhathom Pharmaceuticals0.00%+3.62%+5.91%-13.03%+335.14%PLRXPliant Therapeutics0.00%-0.83%-11.11%-0.83%-28.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINVAInnoviva$22.95-0.2%$23.01$16.52▼$25.15$1.70B0.38712,445 shs244,956 shsKNSAKiniksa Pharmaceuticals International$56.28-2.3%$46.40$24.85▼$58.20$4.31B0.17706,780 shs267,271 shsNWBONorthwest Biotherapeutics$0.21-2.4%$0.21$0.19▼$0.37$343.21M-0.742.90 million shs1.83 million shsPHATPhathom Pharmaceuticals$12.29-4.5%$11.52$2.21▼$18.31$979.80M0.571.22 million shs584,428 shsPLRXPliant Therapeutics$1.21+1.3%$1.29$1.09▼$1.95$74.61M1.2696,746 shs162,229 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINVAInnoviva0.00%-1.07%+0.52%+10.05%+23.45%KNSAKiniksa Pharmaceuticals International0.00%+26.74%+13.21%+22.93%+99.89%NWBONorthwest Biotherapeutics0.00%+2.31%-1.63%-30.07%-34.01%PHATPhathom Pharmaceuticals0.00%+3.62%+5.91%-13.03%+335.14%PLRXPliant Therapeutics0.00%-0.83%-11.11%-0.83%-28.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINVAInnoviva 2.57Moderate Buy$34.8052.50% UpsideKNSAKiniksa Pharmaceuticals International 2.67Moderate Buy$60.867.18% UpsideNWBONorthwest Biotherapeutics 0.00N/AN/AN/APHATPhathom Pharmaceuticals 2.88Moderate Buy$25.00103.27% UpsidePLRXPliant Therapeutics 1.80Reduce$3.00146.91% UpsideCurrent Analyst Ratings BreakdownLatest KNSA, PHAT, PLRX, NWBO, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026KNSAKiniksa Pharmaceuticals International Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$62.00 ➝ $64.004/29/2026KNSAKiniksa Pharmaceuticals International CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $60.004/29/2026KNSAKiniksa Pharmaceuticals International WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$58.00 ➝ $59.004/29/2026KNSAKiniksa Pharmaceuticals International Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $57.004/28/2026KNSAKiniksa Pharmaceuticals International Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$58.00 ➝ $71.004/21/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)4/21/2026PHATPhathom Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PLRXPliant Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026KNSAKiniksa Pharmaceuticals International Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/16/2026KNSAKiniksa Pharmaceuticals International WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$53.00 ➝ $58.003/27/2026INVAInnoviva Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B)(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINVAInnoviva$411.33M4.11$4.97 per share4.59$15.71 per share1.45KNSAKiniksa Pharmaceuticals International$677.56M6.41$0.82 per share69.63$7.44 per share7.63NWBONorthwest Biotherapeutics$1.38M249.29N/AN/A($0.04) per share-5.25PHATPhathom Pharmaceuticals$204.89M4.79N/AN/A($6.14) per share-2.00PLRXPliant Therapeutics$1.58M47.62N/AN/A$2.95 per share0.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINVAInnoviva$271.17M$3.057.489.67N/A65.92%37.63%23.60%5/6/2026 (Estimated)KNSAKiniksa Pharmaceuticals International$59.01M$0.9063.4335.05N/A9.69%13.26%9.86%N/ANWBONorthwest Biotherapeutics-$60.16M-$18.24N/AN/AN/A-4,365.89%N/A-142.44%5/15/2026 (Estimated)PHATPhathom Pharmaceuticals-$221.25M-$2.12N/A6.65N/A-76.77%N/A-44.29%N/APLRXPliant Therapeutics-$149.34M-$2.44N/AN/AN/AN/A-68.71%-51.47%5/14/2026 (Estimated)Latest KNSA, PHAT, PLRX, NWBO, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026PLRXPliant Therapeutics-$0.36N/AN/AN/AN/AN/A5/6/2026Q1 2026INVAInnoviva$0.43N/AN/AN/A$101.57 millionN/A4/28/2026Q1 2026KNSAKiniksa Pharmaceuticals International$0.18$0.27+$0.09$0.27$206.11 million$214.27 million3/11/2026Q4 2025PLRXPliant Therapeutics-$0.44-$0.35+$0.09-$0.38N/AN/A2/26/2026Q4 2025PHATPhathom Pharmaceuticals-$0.09-$0.08+$0.01-$0.29$57.44 million$57.58 million2/25/2026Q4 2025INVAInnoviva$0.34$1.94+$1.60$1.94$102.62 million$114.61 million2/24/2026Q4 2025KNSAKiniksa Pharmaceuticals International$0.29$0.17-$0.12$0.17$200.86 million$202.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINVAInnovivaN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINVAInnoviva0.2214.6413.85KNSAKiniksa Pharmaceuticals InternationalN/A3.793.33NWBONorthwest BiotherapeuticsN/A0.060.06PHATPhathom PharmaceuticalsN/A2.212.16PLRXPliant TherapeuticsN/A12.0012.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINVAInnoviva99.12%KNSAKiniksa Pharmaceuticals International53.95%NWBONorthwest Biotherapeutics0.04%PHATPhathom Pharmaceuticals99.01%PLRXPliant Therapeutics97.30%Insider OwnershipCompanyInsider OwnershipINVAInnoviva2.01%KNSAKiniksa Pharmaceuticals International53.48%NWBONorthwest Biotherapeutics2.40%PHATPhathom Pharmaceuticals9.33%PLRXPliant Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINVAInnoviva10074.07 million72.59 millionOptionableKNSAKiniksa Pharmaceuticals International22076.54 million35.60 millionOptionableNWBONorthwest Biotherapeutics201.64 billion1.60 billionNot OptionablePHATPhathom Pharmaceuticals11079.76 million72.32 millionOptionablePLRXPliant Therapeutics9061.92 million57.95 millionOptionableKNSA, PHAT, PLRX, NWBO, and INVA HeadlinesRecent News About These CompaniesPliant Therapeutics (NASDAQ:PLRX) Rating Increased to Hold at Wall Street ZenMay 3 at 1:41 AM | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street ZenMay 3 at 1:05 AM | marketbeat.comPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid TumorsApril 30, 2026 | markets.businessinsider.comPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid TumorsApril 30, 2026 | globenewswire.comWall Street Zen Downgrades Pliant Therapeutics (NASDAQ:PLRX) to SellApril 25, 2026 | marketbeat.comPliant Therapeutics Presents Promising Phase 1b Trial Data for PLN-101095 in Combination with Pembrolizumab for ICI-Refractory Advanced Tumors at AACR 2026April 18, 2026 | quiverquant.comQPliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual MeetingApril 18, 2026 | globenewswire.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Reduce" by AnalystsApril 15, 2026 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Shares Up 1.6% - Should You Buy?April 14, 2026 | marketbeat.comPliant Therapeutics Launches New $50 Million ATM ProgramMarch 30, 2026 | tipranks.comPliant Therapeutics (PLRX) price target decreased by 17.95% to 2.72March 27, 2026 | msn.comPliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in ...March 18, 2026 | bakersfield.comBPliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual MeetingMarch 18, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pliant Therapeutics (PLRX) and Cytokinetics (CYTK)March 14, 2026 | theglobeandmail.comPliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial ResultsMarch 12, 2026 | finanznachrichten.dePliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial ResultsMarch 11, 2026 | globenewswire.comAnalysts Are Neutral on These Healthcare Stocks: Pliant Therapeutics (PLRX), Summit Therapeutics (SMMT)March 10, 2026 | theglobeandmail.comPliant Therapeutics Extends Stockholder Rights Agreement ExpirationMarch 3, 2026 | tipranks.comPliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill ExpirationFebruary 24, 2026 | seekingalpha.comPliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science ConferenceFebruary 23, 2026 | globenewswire.comPliant Therapeutics (NASDAQ:PLRX) CEO Sells $114,400.00 in StockJanuary 23, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKNSA, PHAT, PLRX, NWBO, and INVA Company DescriptionsInnoviva NASDAQ:INVA$22.95 -0.04 (-0.17%) As of 02:30 PM Eastern This is a fair market value price provided by Massive. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Kiniksa Pharmaceuticals International NASDAQ:KNSA$56.28 -1.34 (-2.32%) As of 02:30 PM Eastern This is a fair market value price provided by Massive. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Northwest Biotherapeutics OTCMKTS:NWBO$0.21 -0.01 (-2.42%) As of 02:14 PM EasternNorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.Phathom Pharmaceuticals NASDAQ:PHAT$12.29 -0.58 (-4.54%) As of 02:30 PM Eastern This is a fair market value price provided by Massive. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Pliant Therapeutics NASDAQ:PLRX$1.20 +0.02 (+1.26%) As of 02:30 PM Eastern This is a fair market value price provided by Massive. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas onsemi Stock Dips After Earnings: Why the Dip Is Buyable Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom Atomic Dividends: Big Tech's New Energy Bet Monolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Leading Insider Sales: April Activity Ramps in These Stocks The New Fed Chair Trade: Who Wins When Warsh Takes the Helm? A Prada Payday: Is AMC Back in Style? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
